Gene Therapy SGT-001 Improves Lung Function in DMD Boys in Trial

Gene Therapy SGT-001 Improves Lung Function in DMD Boys in Trial

307866

Gene Therapy SGT-001 Improves Lung Function in DMD Boys in Trial

Treatment with SGT-001 — Solid Biosciences’ gene therapy candidate for Duchenne muscular dystrophy (DMD) — improves lung function, according to data from the first six patients enrolled in the ongoing IGNITE DMD clinical trial. The improvements, seen one year after a single infusion of the SGT-001 gene therapy into the vein, included better percent predicted peak expiratory flow, called PEF% predicted — a measure of how fast air can be exhaled from the lungs — and forced…

You must be logged in to read/download the full post.